D DBV Technologies SA
D
Închisă
2.374 -1.58
Rezumat
Modificarea prețului
24h
Minim
2.352
Maxim
2.402
Venit | -2.8M -50M |
|---|---|
Vânzări | -200K 700K |
EPS | -0.05 |
Marjă de profit | -7,200 |
Angajați | 170 |
EBITDA | -1.2M -47M |
Următoarele câștiguri | 28 oct. 2026 |
|---|
Capitalizare de piață | -64M 768M |
|---|---|
Deschiderea anterioară | 3.95 |
Închiderea anterioară | 2.374 |
DBV Technologies SA Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
DBV Technologies SA Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.